18 Apr 2024 07:00
REDX PHARMA PLC
("Redx" or the "Company")
Share Purchases by a Director
Alderley Park, UK, 18 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that it has been notified that Lisa Anson, Chief Executive Officer, has on 16 and 17 April 2024 acquired 189,500 Redx ordinary shares at a weighted average price of 10.01 pence per share. Following this, Lisa Anson will hold 751,683 ordinary shares in the Company, representing 0.19 per cent. of the issued share capital.
Further information on the purchases is contained within the disclosure tables below.
For further information, please contact: |
| |||
| ||||
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications ir@redxpharma.com
| T: +44 (0)1625 469 918 | |||
SPARK Advisory Partners (Nominated Adviser) | T: +44 (0)203 368 3550 | |||
Matt Davis/ Adam Dawes | ||||
Panmure Gordon (UK) Limited (Broker) | T: +44 (0)207 886 2500 | |||
Rupert Dearden/ Freddy Crossley/ Emma Earl | ||||
FTI Consulting | T: +44 (0)203 727 1000 | |||
Simon Conway/ Ciara Martin | ||||
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company expects a number of data points during 2024 including from lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), in development for interstitial lung disease and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development and is expected to report healthy volunteer data; and Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data, following which Redx will seek a partner for ongoing development.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||||
a) | Name | Lisa Anson
| ||||||
2. | Reason for the notification | |||||||
a) | Position / status | Chief Executive Officer
| ||||||
b) | Initial notification / Amendment | Initial notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Redx Pharma plc
| ||||||
b) | LEI | 213800HMS4EBXO589Y37
| ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 1 pence each in Redx Pharma plc
ISIN for Redx Pharma plc Ordinary Shares: GB00BSNB6S51
| ||||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||||
c) | Prices(a) and volume(s) |
| ||||||
d) | Aggregated information - Aggregated volume - Price |
115,000 9.375p | ||||||
e) | Date of the transaction | 16 April 2024 | ||||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON)
| ||||||
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||||
a) | Name | Lisa Anson
| ||||||
2. | Reason for the notification | |||||||
a) | Position / status | Chief Executive Officer
| ||||||
b) | Initial notification / Amendment | Initial notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Redx Pharma plc
| ||||||
b) | LEI | 213800HMS4EBXO589Y37
| ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 1 pence each in Redx Pharma plc
ISIN for Redx Pharma plc Ordinary Shares: GB00BSNB6S51
| ||||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||||
c) | Prices(a) and volume(s) |
| ||||||
d) | Aggregated information - Aggregated volume - Price |
74,500 11p | ||||||
e) | Date of the transaction | 17 April 2024 | ||||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON)
| ||||||